Sumitomo Chemical Company (4005) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
3 Feb, 2026Executive summary
Core operating income and net income attributable to owners rose sharply year-on-year, surpassing forecasts, driven by strong Sumitomo Pharma sales, robust segment performance, and gains from business divestitures, particularly in Essential & Green Materials.
Significant improvements were seen in Sumitomo Pharma, Essential & Green Materials, and Agro & Life Solutions, with notable one-time gains and robust product sales.
Sales revenue for Q3 FY2025 was ¥1,706.3 billion, down ¥198.5 billion year-over-year, but all profit categories increased significantly, with core operating income at ¥186.8 billion and net income attributable to owners at ¥87.4 billion, up 205.7% year-over-year.
Net income attributable to owners exceeded the third quarter forecast, but significant non-recurring losses are expected in Q4.
Upward revisions were made to the full-year forecast, with sales revenue now expected at ¥2,300.0 billion and net income attributable to owners at ¥55.0 billion.
Financial highlights
Q3 FY2025 sales revenue was ¥1,706.3 billion, down 10.4% year-over-year; core operating income was ¥186.8 billion, up 211.1%; operating income reached ¥180.4 billion, up 24.1% year-over-year.
Net income attributable to owners was ¥87.4 billion, up 205.7% year-over-year, with basic EPS at ¥53.38.
Free cash flow for Q3 FY2025 was ¥71.8 billion, down from ¥197.5 billion year-over-year.
ROE improved to 9.0% from 3.0% in the prior year.
Overseas sales revenue ratio increased to 71.2%.
Outlook and guidance
Full-year FY2025 sales revenue forecast revised upward to ¥2,300.0 billion, core operating income to ¥200.0 billion, and net income attributable to owners to ¥55.0 billion.
Year-end dividend per share increased to ¥7.5, annual dividend to ¥13.5, with a payout ratio of about 40%.
ICT & Mobility Solutions segment profit guidance raised by ¥2 billion due to higher semiconductor material shipments.
Profit from business activities expected to improve significantly due to structural reforms.
Latest events from Sumitomo Chemical Company
- V-shaped recovery in core income, portfolio upgrades, and strong IT/Pharma performance.4005
Q2 202517 Jan 2026 - Q3 FY2024 delivered a strong profit rebound and segment growth, with guidance maintained.4005
Q3 20259 Jan 2026 - V-shaped recovery and growth driven by Agro, ICT, and reforms, targeting 200bn yen by FY2027.4005
Status Update16 Dec 2025 - FY2024 saw a sharp profit rebound and improved cash flow, with higher dividends ahead.4005
Q4 202520 Nov 2025 - Core operating income rose sharply despite lower sales and FX losses; outlook is positive.4005
Q1 202616 Nov 2025 - Profit rebounded sharply on pharma gains and asset sales, with a raised full-year outlook.4005
Q2 20264 Nov 2025 - Growth strategy leverages tech strengths, reforms, and portfolio upgrades for resilience and efficiency.4005
Status Update25 Sep 2025 - Profitability returned, led by IT-related Chemicals and improved segment results.4005
Q1 202513 Jun 2025